Analgesic Efficacy of Maxigesic in Breast Cancer Surgery
Status:
Recruiting
Trial end date:
2025-02-26
Target enrollment:
Participant gender:
Summary
The present study aims to find a perioperative analgesic method that provides sufficient
analgesia while reducing immune compromise in cancer surgery. This study is to investigate
the analgesic effect and safety of Maxigesic inj. (a combination of acetaminophen 1000 mg and
ibuprofen 300 mg), which is added to opioid-based IV-PCA in patients undergoing breast cancer
surgery.